Texas Yale Capital Corp. Sells 62,325 Shares of Kenvue Inc. $KVUE

Key Points

• Texas Yale Capital Corp. cut its Kenvue stake by 86.2% in the fourth quarter, selling 62,325 shares and leaving it with 10,000 shares worth about $172,000.
• Kenvue reported a strong recent quarter, with EPS of $0.32 topping estimates and revenue of $3.91 billion, up 4.5% year over year.
• The company also paid a quarterly dividend of $0.2075 per share, equating to an annualized yield of about 4.8%, while analysts currently rate the stock a consensus Hold.

Texas Yale Capital Corp. lowered its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 86.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,000 shares of the company's stock after selling 62,325 shares during the quarter. Texas Yale Capital Corp.'s holdings in Kenvue were worth $172,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Arrowstreet Capital Limited Partnership bought a new stake in shares of Kenvue in the 2nd quarter worth about $6,528,000. Jump Financial LLC lifted its holdings in shares of Kenvue by 210.6% in the 2nd quarter. Jump Financial LLC now owns 54,823 shares of the company's stock worth $1,147,000 after acquiring an additional 37,170 shares during the last quarter. AXA S.A. lifted its holdings in shares of Kenvue by 21.1% in the 2nd quarter. AXA S.A. now owns 48,892 shares of the company's stock worth $1,023,000 after acquiring an additional 8,524 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in shares of Kenvue by 219.1% in the 2nd quarter. NewEdge Advisors LLC now owns 97,481 shares of the company's stock worth $2,040,000 after acquiring an additional 66,930 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Kenvue by 0.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,873,705 shares of the company's stock worth $39,217,000 after acquiring an additional 10,885 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Kenvue Trading Up 0.6%

Shares of KVUE opened at $17.39 on Tuesday. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $23.78. The company has a 50-day moving average of $17.40 and a 200 day moving average of $17.47. The firm has a market capitalization of $33.38 billion, a price-to-earnings ratio of 20.45, a PEG ratio of 1.31 and a beta of 0.55. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.05. The business had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The company's revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.24 EPS. On average, research analysts expect that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were given a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. Kenvue's dividend payout ratio (DPR) is 97.65%.

Insider Buying and Selling

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the firm's stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.59% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on KVUE shares. Barclays lowered their target price on shares of Kenvue from $19.00 to $18.00 and set an "equal weight" rating for the company in a report on Tuesday, April 14th. Canaccord Genuity Group raised their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock a "hold" rating in a report on Wednesday, February 18th. Citigroup lowered their target price on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a report on Wednesday, April 15th. Weiss Ratings lowered shares of Kenvue from a "hold (c)" rating to a "hold (c-)" rating in a report on Friday. Finally, Zacks Research upgraded shares of Kenvue from a "hold" rating to a "strong-buy" rating in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Kenvue presently has a consensus rating of "Hold" and an average target price of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.